Promising Advances in Pancreatic Cancer: ASCO 2025 Highlights
Phase III PANOVA‑3 trials show that Tumour‑Treating Fields improve overall survival in locally advanced pancreatic ductal adenocarcinoma.
The ASCO 2025 conference highlighted several promising advances in pancreatic cancer, including Phase III trials that demonstrate improved overall survival with tumour‑treating fields (TTFields) when combined with gemcitabine and nab‑paclitaxel, as well as other novel combination regimens and a vaccine approach, offering new therapeutic options for a disease with historically poor outcomes.
Pancreatic cancer has one of the lowest survival rates among solid tumours. The demonstrated two‑month overall‑survival benefit with TTFields offers a potential new frontline therapy that could translate into meaningful lengthening of life and reduction of pain‑related morbidity for patients with locally advanced disease.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.